Providers

On the eve of the 40th anniversary of the CDC’s first report on what would become known as HIV/AIDS, Perry N. Halkitis, PhD, MS, MPH, sends out an urgent call to continue this fight and rededicate resources to finding a cure.

Christine Ko, MD, professor of dermatology and pathology at Yale University, reflects on her use of telehealth and how it allowed her to establish and maintain emotional connections with her patients, all at high risk of skin cancer.

In the June 5, 1981, issue of the Morbidity and Mortality Weekly Report from the CDC, a brief 3-page report appeared describing 5 rare cases of Pneumocystis carinii pneumonia among 5 homosexual men in Los Angeles. Our full Q&A with the lead author on that report, Michael Gottlieb, MD, will appear next week. Below is a video preview.

Recent coverage from Targeted Oncology® highlights how combination therapies are impacting the treatment spectrum for chronic lymphocytic leukemia (CLL).

With a variety of treatments available for chronic lymphocytic leukemia (CLL), a disease that is extremely heterogeneous, clinicians are faced with a challenging task to choose the right treatment for a patient.

Sessions, posters, and late-breaking trials at the American College of Cardiology’s 70th Scientific Session offer updates on vericiguat, SGLT2 inhibitors, sacubitril/valsartan, and heart failure therapies still in the pipeline.

The COVID-19 pandemic brought together the world and taught health systems how to be resilient and adapt to both predictable and unpredictable changes, said the panelists during the plenary on day 1 of Virtual ISPOR 2021.

Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).

New research is helping to move the field forward for diffuse large B-cell lymphoma (DLBCL).

Despite expanded use of precision medicine, there remain a myriad of barriers hindering its implementation in day-to-day practice.

To mark National Women's Health Week, The American Journal of Managed Care® assesses challenges posed to women in the United States by the pandemic and looks ahead to potential long-term consequences.

We’re going to celebrate and refocus on the science, reflect and share lessons learned from the pandemic, and really engage our audience in discussions that cover care guidelines and nontraditional pathways of care, said Pamela Bowe Morris, MD, chair of ACC.21.

Understanding that there is a third type of heart failure will further our understanding of the disease, noted Clyde W. Yancy, MD, MSc, chief of cardiology and vice dean for diversity and inclusion at Northwestern University's Feinberg School of Medicine.

Asthma exacerbations among Black/African American and Hispanic/Latinx adults with moderate-to-severe asthma decreased by approximately 40% during the COVID-19 pandemic, particularly among individuals who worked outside the home and those without type 2 inflammation.

There is a persistent gap in heart failure care regarding administration of life-saving therapies outlined in clinical practice guidelines and consensus documents, noted James Jacuzzi, MD, of Harvard Medical School and an ACC trustee.

On this episode of Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, talks with the founder and CEO of ConsejoSano, a patient engagement firm working with diverse, multicultural, multilingual populations about the importance of building relationships and trust when trying to understand opinions and beliefs about COVID-19 vaccination.

Among a group of primary care accountable care organizations, patients with hypertension were 50% less likely to have a blood pressure recorded in April compared with February.

William Shrank, MD, MSHS, the chief medical officer of Humana, discusses how the company is trying to overcome any vaccine hesitancy both in its workforce and in its insured member population.

The frequency of low-value care can be reduced by a respectful, data-driven process anchored in nonjudgmental communication and explicit core values.

The study results were released as nephrologists and others are awaiting the findings of a joint task force of 2 national kidney organizations looking at alternative approaches to estimating glomerular filtration rate.

Despite the FDA approving 29 biosimilars, none have achieved interchangeability status. Boehringer Ingelheim thinks its adalimumab biosimilar, Cyltezo, may be the first.

Patients with pulmonary arterial hypertension (PAH) who have comorbidities or advanced age who are treated with a monotherapy have comparable outcomes to patients on combination therapies.

Posters from the Academy of Managed Care Pharmacy annual meeting evaluated real-world evidence on adherence to biosimilars and barriers to biosimilar adoption.

Tuesday marked the first of 3 days of hearings on whether checkpoint inhibitors should keep indications after follow-up studies failed to show benefits that led to accelerated approval.

The authors suggest that assessment of patient-centered care may be improved by flagging probable discordance between a patient’s preferences and their treatment care plan.

Risk of infection topped the list of concerns among patients with multiple sclerosis (MS) who altered their usual care routines during the COVID-19 pandemic.

Unsurprisingly, the use of telemedicine grew exponentially during the COVID-19 pandemic, but those changes are not here to stay without major policy changes, according to speakers at the American Academy of Dermatology Virtual Meeting Experience 2021.

With immunosuppression, self-regulatory mechanisms may start to decrease, and these are the patients who develop skin cancers more frequently, said Rajiv Nijhawan, MD, UT Southwestern Medical Center.

Posters presented at the American Academy of Dermatology Virtual Meeting Experience show ruxolitinib cream was effective at treating atopic dermatitis (AD) regardless of previous treatments and in patients with more severe disease.

Until now, treatments for atopic dermatitis have had safety concerns, but a new understanding of the disease has led to novel and exciting agents being developed, according to Emma Guttman, MD, PhD, of Mount Sinai.